The Medicines for Europe association represent the pharmaceutical companies supplying the largest share of medicines across Europe and is the voice of the generic, biosimilar and value-added industries.
It holds its 5th conference on value-added medicines on November 7th, 2023, in Brussels. One of the topics to be addressed in this conference is repurposing of medicines, which has emerged as an important strategy to address unmet medical need, especially in the pediatric field.
Laurent Martin, Orphelia Pharma’s Chief Pharmaceutical Affairs Officer, will contribute to the discussion with the story and market access of Kigabeq, the first pediatric formulation of vigabatrin for the treatment of a rare form of encephalopathic epilepsy: West syndrome.
An event not to be missed! More information can be found at: https://www.medicinesforeurope.com/events/vam23/